Skip to Primary Navigation

Skip to main content

Rebate debate redux: Revisiting 340B drug pricing

Prescription desk at US pharmacy
Photo: Spencer Platt/Getty Images

Kevin Kinsella

4 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

In a high-stakes struggle over the fate of the popular drug pricing program, neither the Trump administration nor safety-net hospital groups seem willing to cede the field.

On February 17, 2026, the Health Resources and Services Administration (HRSA) issued a request for information (RFI) seeking comment on the use of manufacturer rebates to establish ceiling prices for drugs in the federal 340B program.

The RFI was seen by regulatory observers as an early indication that the Trump administration intended

, , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience